Gilead Sciences Stock Performance
| GILD Stock | USD 92.41 1.06 1.16% |
On a scale of 0 to 100, Gilead Sciences holds a performance score of 15. The company retains a Market Volatility (i.e., Beta) of 0.47, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Gilead Sciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Gilead Sciences is expected to be smaller as well. Please check Gilead Sciences' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Gilead Sciences' current trending patterns will revert.
Risk-Adjusted Performance
15 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain essential indicators, Gilead Sciences exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.17 | Five Day Return 2.91 | Year To Date Return 11.03 | Ten Year Return (7.87) | All Time Return 14.5 K |
Forward Dividend Yield 0.0337 | Payout Ratio 0.6953 | Last Split Factor 2:1 | Forward Dividend Rate 3.08 | Dividend Date 2024-12-30 |
| Gilead Sciences dividend paid on 27th of September 2024 | 09/27/2024 |
1 | Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline | 11/12/2024 |
2 | Gilead Prices 3.5 Billion of Senior Unsecured Notes | 11/14/2024 |
3 | FDA Accepts SNY and REGNs Dupixent Re-Submitted sBLA for Urticaria | 11/18/2024 |
4 | TOUCH, la Alianza de Personas de la Raza Negra contra el Cncer de Seno y sus aliados presentan el centro de recursos el Oasis de TNBC para Personas de la Raza N... | 11/19/2024 |
5 | FirstLight and Maine Connectivity Authority Sign Agreement to Build 450 Miles of Fiber in Western Maine | 11/20/2024 |
6 | Cypress Capital Group Reduces Holdings in Gilead Sciences, Inc. | 11/21/2024 |
7 | Gilead Announces Layoffs Amid Strong Q3 Performance, HIV Drug Sales Surge | 11/22/2024 |
8 | Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gi... | 11/26/2024 |
| Begin Period Cash Flow | 5.4 B | |
| Total Cashflows From Investing Activities | -2.3 B |
Gilead |
Gilead Sciences Relative Risk vs. Return Landscape
If you would invest 7,827 in Gilead Sciences on August 30, 2024 and sell it today you would earn a total of 1,414 from holding Gilead Sciences or generate 18.07% return on investment over 90 days. Gilead Sciences is currently generating 0.2738% in daily expected returns and assumes 1.4193% risk (volatility on return distribution) over the 90 days horizon. In different words, 12% of stocks are less volatile than Gilead, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gilead Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gilead Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gilead Sciences, and traders can use it to determine the average amount a Gilead Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1929
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GILD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.42 actual daily | 12 88% of assets are more volatile |
Expected Return
| 0.27 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 15 85% of assets perform better |
Based on monthly moving average Gilead Sciences is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gilead Sciences by adding it to a well-diversified portfolio.
Gilead Sciences Fundamentals Growth
Gilead Stock prices reflect investors' perceptions of the future prospects and financial health of Gilead Sciences, and Gilead Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gilead Stock performance.
| Return On Equity | 0.0056 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 132.06 B | ||||
| Shares Outstanding | 1.25 B | ||||
| Price To Earning | 359.42 X | ||||
| Price To Book | 6.16 X | ||||
| Price To Sales | 4.02 X | ||||
| Revenue | 27.12 B | ||||
| Gross Profit | 21.62 B | ||||
| EBITDA | 7.61 B | ||||
| Net Income | 5.61 B | ||||
| Cash And Equivalents | 6.14 B | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 24.99 B | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 14.83 X | ||||
| Cash Flow From Operations | 8.01 B | ||||
| Earnings Per Share | 0.09 X | ||||
| Market Capitalization | 113.85 B | ||||
| Total Asset | 62.12 B | ||||
| Retained Earnings | 16.3 B | ||||
| Working Capital | 4.8 B | ||||
| Current Asset | 1.18 B | ||||
| Current Liabilities | 104.89 M | ||||
About Gilead Sciences Performance
By analyzing Gilead Sciences' fundamental ratios, stakeholders can gain valuable insights into Gilead Sciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Gilead Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Gilead Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 100.38 | 95.36 | |
| Return On Tangible Assets | 0.21 | 0.22 | |
| Return On Capital Employed | 0.15 | 0.08 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.25 | 0.26 |
Things to note about Gilead Sciences performance evaluation
Checking the ongoing alerts about Gilead Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gilead Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More |
- Analyzing Gilead Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gilead Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Gilead Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gilead Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gilead Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gilead Sciences' stock. These opinions can provide insight into Gilead Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |